Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00497770 · ClinicalTrials.gov registry record
An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed
A clinical trial, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- 434
- Enrollment target
NCT00497770: Completed study, sponsored by Eli Lilly and Company.
NCT00497770 is a clinical trial that has completed, run by Eli Lilly and Company. The registered enrollment target is 434 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00497770 has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- 434 participants
- Enrollment target
Study Summary
This large, non-randomized observational study is being conducted to provide data about the impact of ethnic origin on outcomes and resource utilization during the 2nd line treatment of non-small cell lung cancer (NSCLC) in a routine medical care setting.
Primary Outcome
Disease Control Rate \[DCR\] is the percentage of participants with Complete Response (CR), Partial Response (PR), Stable Disease (SD), and SD or Incomplete Response (SI). Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. CR=disappearance of all target lesions; PR=30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=20% increase in sum of longest diameter of target lesions; SD=small changes not meeting above criteria; SI=persistence of
Interventions
- DRUG Pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 434 participants |
| Start Date | 2007-02 |
| Est. Completion | 2011-03 |
What the finished NCT00497770 record still lists
NCT00497770 is an observational study that tracks outcomes without assigning an intervention. The registered 434 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Pemetrexed is the first listed.
NCT00497770 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00497770 about?
NCT00497770 is a clinical study titled "An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed". This large, non-randomized observational study is being conducted to provide data about the impact of ethnic origin on outcomes and resource utilization during the 2nd line treatment of non-small cell lung cancer (NSCLC) in a routine medical care setting.
What is the current status of trial NCT00497770?
This trial is currently completed. The enrollment target is 434 participants. The study started on 2007-02. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00497770?
The interventions under investigation include: Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00497770?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04743245 · 434 participants · NA
Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
- NCT06471920 · 434 participants · NA
Improving Health for Patients With Chronic LBP in Rural Communities Through Telerehabilitation
- NCT07094113 · 434 participants · Phase 1
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- NCT05563220 · 435 participants · Phase 1
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia